Does preoperative platelet count and thrombocytosis play a prognostic role in patients undergoing nephrectomy for renal cell carcinoma? Results of a comprehensive retrospective series

World Journal of Urology

Volumn 31, Issue 5, 2013, Pages 1309-1316

  Brookman May, Sabine ^a   May, Matthias ^b   Ficarra, Vincenzo ^c   Kainz, Manuela Christine ^e   Kampel Kettner, Karin ^e   Kohlschreiber, Stephanie ^d   Wenzl, Valentina ^d   Schneider, Meike ^f   Burger, Maximilian ^d   Wieland, Wolf F ^d   Otto, Wolfgang ^d   Tilki, Derya ^a   Gilfrich, Christian ^b   Hohenfellner, Markus ^f   Pahernik, Sascha ^f   Chromecki, Thomas F ^e   Stief, Christian ^a   Zigeuner, Richard ^e  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Urologische Klinik   (Germany)

^c Department of Urology   (Belgium)

^d UNIVERSITY OF REGENSBURG   (Germany)

^e MEDICAL UNIVERSITY OF GRAZ   (Austria)

^f UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Cancer specific survival; Nephrectomy; Preoperative platelet level; Prognosis; Renal cell carcinoma; Thrombocytosis

Indexed keywords

AGED; ARTICLE; BLOOD; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; KIDNEY CARCINOMA; KIDNEY TUMOR; MALE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; NEPHRECTOMY; PREDICTIVE VALUE; PREOPERATIVE CARE; PROGNOSIS; RETROSPECTIVE STUDY; STATISTICAL MODEL; SURVIVAL RATE; THROMBOCYTE COUNT; THROMBOCYTOSIS; TREATMENT OUTCOME;

AGED; CARCINOMA, RENAL CELL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MODELS, STATISTICAL; MULTIVARIATE ANALYSIS; NEPHRECTOMY; PLATELET COUNT; PREDICTIVE VALUE OF TESTS; PREOPERATIVE CARE; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; THROMBOCYTOSIS; TREATMENT OUTCOME;

EID: 84884818310     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-012-0931-0     Document Type: Article

References (31)

1. Ljungberg B, Campbell SC, Cho HY, Jacqmin D, Lee JE, Weikert S et al (2011) The epidemiology of renal cell carcinoma. Eur Urol 60(4): 615-621.
2. Crispen PL, Breau RH, Allmer C, Lohse CM, Cheville JC, Leibovich BC et al (2011) Lymph node dissection at the time of radical nephrectomy for high-risk clear cell renal cell carcinoma: indications and recommendations for surgical templates. Eur Urol 59: 18-23.
3. Ficarra V, Brunelli M, Cheng L, Kirkali Z, Lopez-Beltran A, Martignoni G et al (2010) Prognostic and therapeutic impact of the histopathologic definition of parenchymal epithelial renal tumors. Eur Urol 58(5): 655-668.
4. Kim HS, Kim WS, Park SH, Jung CW, Choi HY, Lee HM et al (2010) Molecular biomarkers for advanced renal cell carcinoma: implications for prognosis and therapy. Urol Oncol 28(2): 157-163.
5. Karakiewicz PI, Suardi N, Capitanio U, Jeldres C, Ficarra V, Cindolo L et al (2009) A preoperative prognostic model for patients treated with nephrectomy for renal cell carcinoma. Eur Urol 55: 287-295.
6. Saito K, Tatokoro M, Fujii Y, Iimura Y, Koga F, Kawakami S et al (2009) Impact of C-reactive protein kinetics on survival of patients with metastatic renal cell carcinoma. Eur Urol 55(5): 1145-1153.
7. Nieswandt B, Hafner M, Echtenacher B, Männel DN (1999) Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res 59: 1295-1300.
8. Suppiah R, Shaheen PE, Elson P, Misbah SA, Wood L, Motzer RJ et al (2006) Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma. Cancer 107: 1793-1800.
9. Brookman-Amissah S, Kendel F, Spivak I, Pflanz S, Roigas J, Klotz T et al (2009) Impact of clinical variables on predicting disease-free survival of patients with surgically resected renal cell carcinoma. BJU Int 103: 1375-1380.
10. Karakiewicz PI, Trinh QD, Lam JS, Tostain J, Pantuck AJ, Belldegrun AS et al (2007) Platelet count and preoperative haemoglobin do not significantly increase the performance of established predictors of renal cell carcinoma-specific mortality. Eur Urol 52: 1428-1436.
11. Bensalah K, Leray E, Fergelot P, Rioux-Leclercq N, Tostain J, Guillé F et al (2006) Prognostic value of thrombocytosis in renal cell carcinoma. J Urol 175: 859-863.
12. Erdemir F, Kilciler M, Bedir S, Ozgok Y, Coban H, Erten K (2007) Clinical significance of platelet count in patients with renal cell carcinoma. Urol Int 79: 111-116.
13. Wosnitzer M, Polland A, Hai Q, Hruby G, McKiernan J (2011) Role of preoperative platelet level in clinical and pathological outcomes after surgery for renal cortical malignancies. BJU Int 108: 73-79.
14. Cho DS, Kim SJ, Lee SH, Ahn HS, Kim YS, Kim SI (2011) Prognostic significance of preoperative C-reactive protein elevation and thrombocytosis in patients with non-metastatic renal cell carcinoma. Korean J Urol 52: 104-109.
15. Ito K, Asano T, Yoshii H, Satoh A, Sumitomo M, Hayakawa M (2006) Impact of thrombocytosis and C-reactive protein elevation on the prognosis for patients with renal cell carcinoma. Int J Urol 13: 1365-1370.
16. Patel A, Bhavan R, Somani B, Nabi G (2010) Correlation of percentage changes in platelet counts with recurrence rate following radical nephrectomy. Indian J Urol 26: 183-187.
17. Göǧüş C, Baltaci S, Filiz E, Elhan A, Bedük Y (2004) Significance of thrombocytosis for determining prognosis in patients with localized renal cell carcinoma. Urology 63: 447-450.
18. Inoue K, Kohashikawa K, Suzuki S, Shimada M, Yoshida H (2004) Prognostic significance of thrombocytosis in renal cell carcinoma patients. Int J Urol 11: 364-367.
19. Lee SE, Byun SS, Han JH, Han BK, Hong SK (2006) Prognostic significance of common preoperative laboratory variables in clear cell renal cell carcinoma. BJU Int 98: 1228-1232.
20. Ljungberg B, Cowan NC, Hanbury DC, Hora M, Kuczyk MA, Merseburger AS et al (2010) EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol 58: 398-406.
21. Greene FL, Gospodarowicz M, Wittekend C et al (2009) American joint committee on cancer (AJCC) staging manual, 7th edn. Springer, Philadalphia, PA.
22. Kovacs G, Akhtar M, Beckwith BJ, Bugert P, Cooper CS, Delahunt B et al (1997) The Heidelberg classification of renal cell tumors. J Pathol 183: 131-133.
23. Fuhrman S, Lasky LC, Limas L (1982) Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 6: 655-663.
24. Harrell FE Jr, Lee KL, Mark DB (1996) Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15: 361-387.
25. DeLong ER, DeLong DM, Clarke-Pearson DL (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44: 837-845.
26. Choueiri TK, Garcia JA, Elson P, Khasawneh M, Usman S, Golshayan AR et al (2007) Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer 110: 543-550.
27. Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C et al (2009) Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 27: 5794-5799.
28. Helley D, Banu E, Bouziane A, Banu A, Scotte F, Fischer AM et al (2009) Platelet microparticles: a potential predictive factor of survival in hormone-refractory prostate cancer patients treated with docetaxel-based chemotherapy. Eur Urol 56: 479-484.
29. Verheul HM, Jorna AS, Hoekman K, Broxterman HJ, Gebbink MF, Pinedo HM (2000) Vascular endothelial growth factor-stimulated endothelial cells promote adhesion and activation of platelets. Blood 96: 4216-4221.
30. Salven P, Orpana A, Joensuu H (1999) Leukocytes and platelets of patients with cancer contain high levels of vascular endothelial growth factor. Clin Cancer Res 5: 487-491.
31. Gnarra JR, Zhou S, Merrill MJ, Wagner JR, Krumm A, Papavassiliou E et al (1996) Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc Natl Acad Sci USA 93: 10589-10594.